Stock ODI ODI PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News ODI Pharma AB

Equities

ODI

SE0013409760

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
5.7 SEK 0.00% Intraday chart for ODI Pharma AB +4.59% +14.00%
22/02 ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 ODI Pharma Sells CBD Skincare Brand for SEK3 Million MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Announcement from the Annual General Meeting in ODI Pharma AB (publ)
AQ
ODI Pharma Sells CBD Skincare Brand for SEK3 Million
MT
ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
AQ
ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
AQ
ODI Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023
AQ
Notice to Annual General Meeting in ODI Pharma AB (publ)
AQ
ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023
AQ
ODI Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
CI
ODI Pharma’s Stock Soars After Exclusive Supplier Deal With Synoptis Pharma
MT
ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.
AQ
ODI Phaa AB Enters into Exclusive Collaboration with Synoptis Pharma Sp. Z o.o
CI
ODI Pharma AB receives loan financing of EUR 350,000
AQ
ODI Pharma AB Receives Loan Financing of EUR 350,000
CI
ODI Pharma AB: Publication of interim report report Q3 2022/2023
AQ
ODI Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
ODI Pharma AB: Publication of half-year report 2022/2023
AQ
ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
CI
ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ODI Stock
  4. News ODI Pharma AB